1.Safety, Tolerability, and Pharmacokinetics of GMDTC for Cadmium Poisoning: A Randomized Phase 1a/1b Trial

2026-04-28

2.Cadmium exposure and cognitive impairment in middle-aged and older adults: Linking neurocognitive deficits with systemic inflammation

2026-04-28

3.Brain gray matter atrophy in adult population with cognitive impairment due to chronic cadmium exposure

2026-04-28

4.GMDTC对顺铂治疗荷瘤大鼠的减毒作用

2026-04-28

5.注射用GMDTC驱镉作用制剂起始剂量与安全性

2026-04-28

6.GMDTC减轻顺铂致大鼠性肾损伤的作用

2026-04-28

7.The in vitro metabolism of GMDTC in liver microsomes of human, monkey, dog, rat and mouse: Metabolic stability assessment, metabolite identification and interspecies comparison

2026-04-28

8.Establishment of LC-MS/MS Method for Determination of GMDTC in Rat Plasma and Its Application in Preclinical Pharmacokinetics

2026-04-28

9.Renal glucose transporters play a role in removal of cadmium from kidney cells mediated by GMDTC – A novel metal chelator

2026-04-28

10.GMDTC Chelating Agent Attenuates Cisplatin-lnduced Systemic Toxicity without Affecting Antitumor Efficacy

2026-04-28

11. 特效驱镉剂GMDTC与金属离子的特异性络合研究

2026-04-28

12.GMDTC驱镉剂量研究

2026-04-28

13.Mobilization and removing of cadmium from kidney by GMDTC utilizing renal glucose reabsorption pathway

2026-04-28